[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cesarean-delivery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cesarean-delivery":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,56,85,118,141,163,196,222,258,289,312,343,371,397,425,449,474,502,523,546,573],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100620851","early-phase-1-topical-tranexamic-acid-to-reduce-blood-loss-during-cesarean-delivery-100620851",false,"NCT07362992","Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery","Does Topical Use of Tranexamic Acid During a Cesarean Delivery Reduce Intra-surgical Bleeding? A Randomized ,Multi-center Trial","Inclusion Criteria:\n\n* Women aged 18 to 51 years\n* Singleton pregnancy\n* Elective cesarean delivery scheduled at ≥37+0 weeks of gestation\n* First or second cesarean delivery only\n* Low transverse uterine incision planned\n* Double-layer uterine closure using 1-0 Vicryl sutures\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to tranexamic acid (TXA)\n* History of bleeding or coagulation disorders\n* Previous postpartum hemorrhage\n* Placenta previa or placenta accreta spectrum\n* Presence of uterine myomas\n* Current use of anticoagulant or antiplatelet medications\n* Planned or intraoperative conversion to general anesthesia\n* Known uterine malformations\n* Known bleeding tendency or thromboembolic disease",true,"FEMALE","18 Years","51 Years",{"count":21,"type":22},112,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","The goal of this clinical trial is to learn whether applying topical tranexamic acid (TXA) directly to the uterine incision during cesarean delivery can reduce surgical bleeding compared to placebo. The study will include pregnant women aged 18-51 undergoing elective cesarean delivery at term (37 weeks or more).\n\nThe main questions it aims to answer are:\n\n* Does topical TXA shorten uterine closure time?\n* Does topical TXA reduce the need for additional hemostatic sutures? Researchers will compare women receiving topical TXA to those receiving placebo (normal saline) to see if TXA reduces intraoperative bleeding and improves surgical outcomes.\n\nParticipants will:\n\n* Be randomly assigned to receive either topical TXA or placebo during cesarean delivery.\n* Have standard surgery and postoperative care identical in both groups.\n* Provide routine clinical data, including hemoglobin levels and recovery outcomes, from their medical records.",[28,29,30,31],"Cesarean Delivery","Postpartum Hemorrhage (PPH)","Intraoperative Blood Loss","Hemostasis",[33,34,35,28,36,37,38,39,40,41,42,43],"Tranexamic Acid","Topical Tranexamic Acid","Hexakapron","Cesarean Section","Elective Cesarean","Postpartum Hemorrhage","Intraoperative Bleeding","Blood Loss Prevention","Uterine Closure","Randomized Controlled Trial","Maternal Outcomes","RECRUITING","2026-07-01",{"date":47,"type":48},"2026-07-02","ACTUAL",{"date":45,"type":48},{"date":51,"type":22},"2028-12-31",{"name":53,"class":54},"Wolfson Medical Center","OTHER_GOV",4,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100645234","pupillary-light-reflex-to-predict-post-spinal-hypotension-in-elective-cesarean-delivery-100645234","NCT07678723","Pupillary Light Reflex to Predict Post-Spinal Hypotension in Elective Cesarean Delivery","Pupillary Light Reflex for Predicting Hypotension Risk After Spinal Anesthesia for Elective Cesarean Section: A Prospective Observational Cohort Study","Inclusion Criteria:\n\nASA II Term pregnancy ≥37 weeks Singleton pregnancy Elective cesarean section Age 18-45 years Written informed consent\n\nExclusion Criteria:\n\nEmergency cesarean section Hypertensive disorders Diabetes mellitus Cardiovascular disease Neurological or autonomic disorders Ophthalmic disease Medications affecting autonomic function BMI \\>40 kg\u002Fm² Failed spinal anesthesia","45 Years",{"count":65,"type":22},200,"OBSERVATIONAL","This prospective observational cohort study investigates whether pre-anesthetic pupillary light reflex (PLR) parameters can predict the risk of hypotension following spinal anesthesia in women undergoing elective cesarean section. Spinal anesthesia-induced hypotension is common, with reported incidence rates of 50-90%, and current predictors such as baseline blood pressure and BMI have limited accuracy. PLR, a sensitive marker of autonomic nervous system balance, may offer a simple, objective, and non-invasive tool for identifying patients at higher risk. The study evaluates pupillary reaction latency and other PLR parameters and correlates them with post-spinal blood pressure changes to determine their predictive value.",[69,70,28],"Hypotension","Spinal Anesthesia",[72,73,70,69,36,74],"Pupillary Light Reflex","Pupillometry","Obstetric Anesthesia","NOT_YET_RECRUITING","2026-06-25",{"date":45,"type":48},{"date":79,"type":22},"2026-06-28",{"date":81,"type":22},"2026-10-31",{"name":83,"class":84},"Al-Azhar University","OTHER",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100643009","video-versus-verbal-preoperative-education-in-elective-cesarean-delivery-100643009","NCT07647601","Video Versus Verbal Preoperative Education in Elective Cesarean Delivery","Effects of Verbal and Video-Based Preoperative Education on Anxiety and Serum Cortisol Response in Women Scheduled for Elective Cesarean Delivery: A Prospective Randomized Controlled Trial","VIDEO-CS","Inclusion Criteria:\n\n* Female participants aged 18 years or older\n* Scheduled for elective cesarean delivery\n* Planned to undergo spinal anesthesia\n* American Society of Anesthesiologists (ASA) physical status I or II\n* Able to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Emergency cesarean delivery\n* History of psychiatric disease\n* Current use of anxiolytic or antidepressant medications\n* Endocrine disorders, including adrenal or thyroid disease\n* Current corticosteroid therapy\n* Previous surgery performed under spinal anesthesia\n* Cognitive impairment or communication difficulties that may interfere with completion of anxiety assessments\n* ASA physical status III, IV, or V",{"count":94,"type":22},140,[96],"NA","This prospective randomized controlled trial aims to evaluate the effects of verbal and video-based preoperative education on anxiety levels and serum cortisol response in women scheduled for elective cesarean delivery under spinal anesthesia.\n\nEligible participants will be randomly assigned to receive either standard verbal education or a standardized video-based educational intervention before surgery. Anxiety levels will be assessed using the State-Trait Anxiety Inventory (STAI-S), and serum cortisol levels will be measured before and after the educational intervention.\n\nThe primary objective is to compare the effectiveness of the two educational methods in reducing preoperative anxiety and physiological stress response.",[99,28,100],"Preoperative Anxiety","Stress Response",[102,103,104,36,70,105,106,107,42],"Preoperative Education","Video-Based Education","Verbal Education","Anxiety","Serum Cortisol","STAI","2026-06-13",{"date":110,"type":48},"2026-06-16",{"date":112,"type":22},"2026-06-10",{"date":114,"type":22},"2026-07-20",{"name":116,"class":84},"Elazıg Fethi Sekin Sehir Hastanesi",1,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":16,"sex":17,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100518401","the-society-for-obstetric-anesthesia-and-perinatology-research-network-general-anesthesia-registry-100518401","NCT06030063","The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry","Inclusion Criteria:\n\n-Pregnant women aged 15-55 who have had a general anesthetic for Cesarean delivery","15 Years","55 Years",{"count":127,"type":22},5000,"The SOAP registry is a prospective, multicenter, electronic registry. The goal is to investigate the indications, mode of airway management, predisposing factors, and obstetric and anesthetic outcomes of pregnant patients who receive general anesthesia for cesarean delivery.",[28,130],"General Anesthesia","2026-06-03",{"date":133,"type":48},"2026-06-04",{"date":135,"type":48},"2024-02-22",{"date":137,"type":22},"2028-12",{"name":139,"class":84},"Yale University",35,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":117},"100599287","a-rct-of-labor-induction-at-39-weeks-in-low---risk-women-in-china-100599287","NCT07082530","A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China","Labor Induction in Low-risk Women at 39 Weeks of Gestation: A Randomized Trial in China","LIRIC","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Singleton pregnancy or twin pregnancy reduced to singleton before 14 weeks.\n3. Gestational age between 38 weeks 4 days or 38 weeks 6 days at randomization.\n4. Eligible for vaginal delivery with a desire for vaginal birth.\n5. Reliable gestational age determination.\n6. Maternal and fetal conditions assessed as low-risk by at least two senior obstetricians, with no indications requiring delivery before 41 weeks.\n7. Ability to understand study information and provide informed consent.\n\nExclusion Criteria:\n\n1. First-trimester ultrasound estimate \\>13 weeks 6 days.\n2. Planned induction before 41 weeks.\n3. Planned cesarean delivery or contraindications to vaginal delivery.\n4. Already delivered, in labor, or ruptured membranes at enrollment.\n5. Placenta previa, vasa previa, placenta accreta, or placental abruption.\n6. Contraindications to induction (e.g., cervical cancer, history of uterine rupture, genital tract malformations, abnormal fetal position, cord prolapse).\n7. Active vaginal bleeding exceeding spotting.\n8. History of cesarean delivery or uterine\u002Fcervical surgery.\n9. Cervical cerclage during this pregnancy.\n10. Maternal conditions not suitable for expectant management beyond 39 weeks (e.g., pregestational diabetes, gestational diabetes requiring insulin, hypertensive disorders, intrahepatic cholestasis of pregnancy).\n11. Fetal conditions not suitable for expectant management beyond 39 weeks (e.g., fetal death, major anomalies, growth restriction, macrosomia, anemia, oligohydramnios, polyhydramnios).\n12. Maternal infections or positive screenings for sexually transmitted pathogens or group B Streptococcus.\n13. Planned delivery at a non-study facility.\n14. Participation in another intervention study affecting delivery management.",{"count":150,"type":22},1074,[96],"The investigators are committed to identifying the optimal timing of delivery for low-risk pregnancies. While current guidelines typically recommend induction at 41 weeks, emerging evidence suggests that elective induction at 39 weeks may lead to improved maternal and neonatal outcomes. The U.S.-based ARRIVE trial demonstrated that induction at 39 weeks significantly reduced cesarean delivery rates compared to expectant management, and a similar randomized controlled trial (French-ARRIVE) is ongoing in France. However, population-specific evidence for the Chinese population remains lacking.\n\nThis study is designed to establish a prospective cohort of low-risk pregnant women in China, comparing the effects of induction at 39 weeks, induction at 41 weeks, and expectant management on cesarean section rates and other maternal and neonatal outcomes. In addition, multi-omics technologies will be employed to analyze cord blood samples-including metabolomics and proteomics-to identify early biomarkers potentially associated with long-term child health. The study will begin with a pilot phase to assess feasibility and inform operational strategies for large-scale implementation.\n\nThe ultimate goal of this project is to generate evidence tailored to the Chinese population to support more individualized decision-making, improve clinical outcomes, and enhance maternal and neonatal safety.",[28],"2026-05-14",{"date":156,"type":48},"2026-05-19",{"date":158,"type":48},"2025-07-30",{"date":160,"type":22},"2027-06-30",{"name":162,"class":84},"Women's Hospital School Of Medicine Zhejiang University",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":171,"briefSummary":173,"conditions":174,"keywords":180,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":117},"100636577","phase-4-adding-dexmedetomidine-or-clonidine-to-spinal-anesthesia-for-cesarean-delivery-100636577","NCT07567495","Adding Dexmedetomidine or Clonidine to Spinal Anesthesia for Cesarean Delivery","Inclusion Criteria:\n\n* Pregnant women undergoing cesarean delivery with spinal anesthesia\n\nExclusion Criteria:\n\n* Significant cardiovascular, psychiatric or respiratory disease\n* using opioids or with chronic pain syndrome\n* Multiple gestation\n* BMI \\>40 kg\u002Fm2\n* Quaternary or greater cesarean\n* \\\u003C 37 weeks gestation\n* Non-English or Spanish speaking\n* planned vertical skin incision\n* planned vertical (classical) uterine incision\n* allergy to clonidine, dexmedetomidine or other study drug",{"count":170,"type":22},150,[172],"PHASE4","This study will examine whether addition of dexmedetomidine or clonidine (two alpha-2 adrenergic agonists) will improve the comfort of patients during spinal anesthesia for cesarean delivery. When added to standard spinal anesthesia consisting of bupivacaine (a local anesthetic) and fentanyl and morphine (two opioids), these medications may decrease some of the pulling\u002Ftugging\u002Fpressure sensations that patients sometimes feel during cesarean delivery, may prolong the anesthetic time, and may decrease postoperative pain.",[28,175,176,177,178,179],"Cesarean Delivery; Neuraxial Opioids","Spinal Anesthesia for Cesarean Section","Dexmedetomidine","Clonidine","Postoperative Analgesia",[181,182,183,184,185,186],"cesarean","dexmedetomidine","clonidine","spinal","anesthesia","Adrenergic alpha-2 Receptor Agonists","2026-04-30",{"date":189,"type":48},"2026-05-05",{"date":191,"type":22},"2026-06",{"date":193,"type":22},"2028-05",{"name":195,"class":84},"Columbia University",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":63,"enrollmentInfo":204,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":205,"conditions":206,"keywords":209,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":117},"100618055","effect-of-gestational-weight-gain-on-spinal-anesthesia-in-elective-cesarean-delivery-100618055","NCT07326644","Effect of Gestational Weight Gain on Spinal Anesthesia in Elective Cesarean Delivery","Effect of Gestational Weight Gain on Regional Anesthesia in Cesarean Patients","GWG-CESA","Inclusion Criteria:\n\n* Pregnant women aged 18-45 years\n\n  * Single pregnancy\n  * Planned elective cesarean section\n  * Spinal anesthesia (regional anesthesia technique)\n  * Pre-pregnancy weight information available (maternal health record, e-Nabız or file record)\n  * Recorded pre-delivery weight information\n  * Gestational weight gain (GWG) calculable according to the IOM 2009 classification\n  * ASA I-II pregnant women\n  * Voluntary participation in the study and informed consent\n\nExclusion Criteria:\n\n* Pregnant women with preeclampsia, severe preeclampsia, eclampsia, or HELLP syndrome\n\n  * Pregnant women with a history of gestational diabetes or pregestational diabetes\n  * Multiple pregnancy (twins, triplets, etc.)\n  * Preterm pregnancy (\\\u003C37 weeks)\n  * Failure of spinal anesthesia or need for conversion to general anesthesia\n  * Lack of pre-pregnancy weight information or weight gain data during pregnancy\n  * Pregnancies with fetal anomalies\n  * Morbid obesity (BMI ≥ 45 kg\u002Fm²)",{"count":65,"type":22},"This prospective, observational, non-interventional study aims to evaluate the effect of gestational weight gain on regional anesthesia characteristics in pregnant women undergoing elective cesarean delivery. No additional intervention, medication, or procedure beyond routine clinical care will be performed. Participants will be classified according to gestational weight gain categories based on the Institute of Medicine (IOM) 2009 guidelines, and spinal anesthesia block characteristics, hemodynamic responses, and perioperative outcomes will be assessed.",[207,208,28],"Gestational Weight Gain","Regional Anesthesia",[210,211,212,213],"Gestational weight gain","Spinal anesthesia","Cesarean delivery","Hemodynamic response","2026-04-20",{"date":216,"type":48},"2026-04-23",{"date":218,"type":48},"2025-12-05",{"date":220,"type":22},"2026-05-10",{"name":116,"class":84},{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":233,"conditions":234,"keywords":241,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":117},"100594452","u-cavit-versus-standard-of-care-for-prevention-of-atonic-postpartum-hemorrhage-after-cesarean-section-in-high-risk-women-100594452","NCT07019623","U-CaVIT Versus Standard of Care for Prevention of Atonic Postpartum Hemorrhage After Cesarean Section in High-risk Women.","Uro-catheter Vacuum-induced Uterine Tamponade (U-CaVIT) Versus Standard of Care for Prevention of Atonic Postpartum Hemorrhage After Cesarean Section in High-risk Women: a Monocentric Randomized-controlled Pilot Study.","UCaVIT Pilot","Inclusion Criteria:\n\n* Signed informed consent\n* Maternal age ≥18 years\n* Gestational age ≥30+0 weeks of pregnancy at day of delivery\n* Vital pregnancy\n* Delivery mode: planned cesarean delivery\n* High-risk patient for PPH specified by the presence of at least one of the following characteristics: Previous PPH, obesity (BMI ≥30 kg\u002Fm2), high parity (patient who has had ≥4 previous births (live or stillborn) at ≥20 weeks of gestation), very advanced maternal age ≥45 years, multiple gestation, polyhydramnios (defined as amniotic fluid index \\> 25 cm or deepest amniotic fluid pocket \\> 8 cm) at admission to delivery, suspected fetal macrosomia (estimated fetal weight ≥ 4500g)\n\nExclusion Criteria:\n\n* Insufficient language skills in German or English to understand and sign informed consent\n* Participation in another interventional study\n* Emergency cesarean section (incl. patients undergoing cesarean after failed vaginal delivery)\n* Subjects who change their delivery plan from vaginal to cesarean section in the course of hospitalization\n* Women with regular and painful contractions and women who do not have time for sufficient consideration\n* Clinical situations in which vacuum-induced uterine tamponade is unlikely to be effective or is contraindicated:\n\n  * Uterine or vaginal anomalies (genital tract congenital anomalies)\n  * Cesarean section due to placenta previa or suspected placenta accreta spectrum\n  * Suspected uterine rupture\n  * Injuries of the cervix or vagina\n  * Submucous or intramural uterine fibroids which are buldging into the uterine cavity\n  * Deep endometriosis \\[16, 17\\]\n* Planned atony-prophylaxis with oxytocin due to contraindication for carbetocin\n* Previous MMC-repair (myelomeningocele-repair)\n* Clinical diagnosis of chorioamnionitis, sepsis\n* Known allergy to silicone\n* Known and proven diagnosis of bleeding disorder or thrombophilia\n* Known thrombocytopenia during second half of pregnancy with thrombocytes \\\u003C 100 G\u002FL\n* Known anemia during second half of pregnancy with Hb\\\u003C80",{"count":231,"type":22},70,[96],"This pilot study aims to assess performance, safety and feasibility of U-CaVIT method (Uro-Catheter Vacuum Induced Tamponade), using the Rüsch® Brillant Silicone Balloon Catheter, an urological catheter, for the prevention of atonic PPH in high-risk women undergoing cesarean delivery.\n\nThe U-CaVIT method has been implemented at the Department of Obstetrics at university hospital of Zurich (USZ) due to temporary supply issues with the Bakri® Balloon Catheter. The Rüsch® Balloon Catheter is used in case of uterine atony when standard first-line uterotonic treatments have failed or in some cases as add-on therapy in non-atonic PPH. In the meantime, the use of U-CaVIT has become standard practice at the USZ for the treatment of atonic PPH, appearing to be user-friendly, clinically effective according to treating physicians, well tolerated by the treated women and cost-saving compared to the previously used Bakri® Balloon.",[235,236,237,238,239,28,240],"Postpartum Hemorrhage (Primary)","Hemorrhage","Postpartum Complication","Delivery ,Complications,Maternal","Pregnancy Complications","Balloon",[38,242,243,244,245,246,247,248],"Delivery complications","high risk patients","Pregnancy","Balloon Catheter","Tamponade","prophylactic","Vacuum-induced tamponade","2026-04-17",{"date":251,"type":48},"2026-04-22",{"date":253,"type":48},"2025-05-28",{"date":255,"type":22},"2026-11",{"name":257,"class":84},"Christian Haslinger",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":23,"phases":268,"briefSummary":269,"conditions":270,"keywords":273,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":286,"leadSponsor":287,"locationsCount":117},"100634055","phase-4-suzetrigine-for-opioid-free-recovery-after-cesarean-delivery-100634055","NCT07534709","Suzetrigine for Opioid-Free Recovery After Cesarean Delivery","Suzetrigine Versus Placebo for Opioid-Free Recovery After Cesarean Delivery: A Randomized Controlled Trial","SPARE","Inclusion Criteria:\n\n* Women aged ≥18 years.\n* Undergoing scheduled or unscheduled cesarean delivery during the current admission, with or without concomitant salpingectomy.\n* Planned delivery under neuraxial anesthesia (spinal, epidural, or combined spinal-epidural).\n* Planned Pfannenstiel skin incision.\n* Able to provide informed consent in English or Spanish.\n* Willing and able to complete required remote follow-up assessments through postoperative day 14 (POD14).\n\nExclusion Criteria:\n\n* Planned provision of breast milk to the neonate during the period of suzetrigine exposure (while the study drug is being taken and for 96 hours after last dose), due to the absence of human lactation safety data for suzetrigine.\\*\n* Known allergy, hypersensitivity, or contraindication to suzetrigine or any component of its formulation.\n* Chronic opioid use, defined as daily opioid use for more than 7 consecutive days in the month prior to delivery, or current treatment for opioid use disorder.\n* Significant hepatic disease, defined as AST or ALT \\>3 times the upper limit of normal or Child-Pugh class B or C.\n* Severe renal impairment, defined as estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin.\n* Concurrent use of medications known to significantly alter suzetrigine metabolism, including strong CYP3A inhibitors or inducers, such as:\n\n  * ketoconazole\n  * ritonavir\n  * carbamazepine\n  * rifampin\n  * St. John's wort (or other agents deemed clinically significant CYP3A modulators by the study investigator team)\n* Planned cesarean delivery under general anesthesia without neuraxial anesthesia.\n* Planned non-Pfannenstiel skin incision (e.g., vertical midline incision).\n* Participation in another interventional pain-management clinical trial during the current hospitalization.\n* Additional operative procedures (excluding salpingectomy) performed at the time of cesarean delivery (e.g., hysterectomy, hernia repair).\n* Inability to provide informed consent or to complete required study procedures and follow-up.\n* Receipt of opioid or sedating medications prior to completion of the informed consent process.\n\n  * Feeding decisions are made independently of study participation. The study does not require participants to alter infant feeding plans; eligibility is determined solely by whether breast milk will be provided to the neonate during the period of study drug exposure (while the study drug is being taken and for 96 hours after last dose). Participants who plan to breastfeed but independently elect not to provide breast milk to the neonate during the period of suzetrigine exposure are eligible.",{"count":267,"type":22},90,[172],"The goal of this clinical trial is to determine whether suzetrigine increases the proportion of patients who remain completely opioid-free from completion of surgery through 72 hours after cesarean delivery.\n\nThe main question it aims to answer is:\n\nDoes adjunctive suzetrigine, when added to a standardized multimodal postoperative analgesic regimen, increase the proportion of patients who remain opioid-free during the first 72 hours after cesarean delivery?\n\nResearchers will compare suzetrigine to a placebo (a look-alike substance that contains no drug) to evaluate this outcome.\n\nParticipants will:\n\n* Receive either suzetrigine or placebo after cesarean delivery\n* Receive standard postoperative pain management, including acetaminophen, nonsteroidal anti-inflammatory drugs, and neuraxial morphine\n* Have opioid medications available as needed for breakthrough pain\n* Be followed during hospitalization and after discharge to assess pain, recovery, and medication use",[28,36,271,272],"Pain, Postoperative","Opioid Consumption, Postoperative",[274,28,275,276,277,278,279,280,281],"suzetrigine","cesarean section","postoperative pain","opioid-free recovery","opioid-sparing","multimodal analgesia","postpartum opioid use","NaV1.8 Inhibitor","2026-04-14",{"date":284,"type":48},"2026-04-16",{"date":191,"type":22},{"date":193,"type":22},{"name":288,"class":84},"University of Texas at Austin",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":63,"enrollmentInfo":295,"targetDuration":4,"studyType":23,"phases":296,"briefSummary":297,"conditions":298,"keywords":300,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":117},"100615442","tap-block-versus-esp-block-in-patients-undergoing-elective-cesarean-section-a-randomized-controlled-trial-100615442","NCT07292662","TAP Block Versus ESP Block in Patients Undergoing Elective Cesarean Section: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 45 years\n* Elective cesarean section\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Allergy to any of the drugs used in the study\n* Heart disease with impaired cardiac function\n* Stage III or higher kidney failure\n* Coagulation disorders (platelets \\\u003C100,000\u002FμL or INR \\>1.5) or severe liver disease\n* Degenerative central nervous system diseases or peripheral neuropathies\n* Previous uterine surgery (e.g., myomectomy)\n* Previous cesarean section\n\nPre-pregnancy weight \\\u003C55 kg",{"count":267,"type":22},[96],"This study is comparing two types of pain relief techniques-TAP block and ESP block-for women having an elective cesarean section. Both techniques involve injecting local anesthetic under ultrasound guidance to numb nerves and reduce pain after surgery. The TAP block mainly relieves pain in the abdominal wall, while the ESP block may reduce both abdominal wall and deeper, organ-related pain. The main goal is to see if there's a difference in pain at rest six hours after surgery. The study will also look at pain at later time points, the amount of opioid medication needed, how quickly women can walk, and when they start breastfeeding.\n\nA total of 156 women will be randomly assigned to receive one of the two blocks after standard spinal anesthesia. Pain will be measured using a simple 0-10 scale at 6, 12, and 24 hours, both at rest and during movement. The study follows strict ethical rules, ensures patient privacy, and all results-whether positive or negative-will be shared to help improve pain management after cesarean delivery.",[28,299],"Regional Anesthesia Block",[301,302,275],"ESP block","TAP block","2026-04-09",{"date":305,"type":48},"2026-04-13",{"date":307,"type":48},"2026-01-07",{"date":309,"type":22},"2027-10",{"name":311,"class":84},"University of Padova",{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":23,"phases":322,"briefSummary":324,"conditions":325,"keywords":328,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":342},"100562588","phase-3-azithromycin-prophylaxis-for-prelabor-cesarean-delivery-trial-100562588","NCT06605118","Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial","Azithromycin Prophylaxis for Prelabor Cesarean Delivery Trial","PRECEDE","Inclusion Criteria:\n\n* ≥ 23 weeks' gestation (ACOG dating criteria)\n* Scheduled or prelabor cesarean delivery\n* Singleton or twin gestation\n\nExclusion Criteria:\n\n* Allergy or contraindication to azithromycin or macrolide antibiotics, including those with a history of cholestatic jaundice\u002Fhepatic dysfunction associated with prior use of azithromycin\n* Chorioamnionitis\n* Bacterial infection (e.g., pyelonephritis) requiring ongoing antibiotic treatment after delivery\n* Premature rupture of membranes (PROM) or labor (i.e., contractions with ongoing cervical change)\n* Fetal demise or known major congenital anomaly\n* Azithromycin treatment within 7 days\n* Planned use of antimicrobial prophylaxis after delivery for any reason\n* Known structural heart disease or active cardiomyopathy (current ejection fraction\\\u003C40%)\n* Known arrhythmia with QT prolongation or taking scheduled medications known to prolong the QT interval such that it would preclude the use of azithromycin\n* Refusal or unable to obtain consent (e.g., language barrier)\n* Participating in another intervention study that influences the primary outcome in this study\n* Participation in this trial in a previous pregnancy. Patients who were screened in a previous pregnancy, but not randomized, do not have to be excluded.",{"count":321,"type":22},8000,[323],"PHASE3","This is a phase-III multi-center double-blind randomized controlled trial of 8,000 individuals undergoing a scheduled or prelabor cesarean delivery who are randomized to either adjunctive azithromycin prophylaxis or to placebo. Both groups also will receive standard of care preoperative antibiotics (excluding azithromycin). The primary endpoint is a maternal infection composite defined as any one of the following up to 6 weeks postpartum: endometritis, wound infection, abscess, septic thrombosis, sepsis, pneumonia, pyelonephritis and breast infection.",[326,327,28],"Obstetrical Complications","Labor and Delivery Complication",[329,330,331,332,333],"cesarean delivery","infection","maternal morbidity","antibiotics","prevention","2026-04-03",{"date":303,"type":48},{"date":337,"type":48},"2024-11-06",{"date":339,"type":22},"2027-11-30",{"name":341,"class":84},"The George Washington University Biostatistics Center",14,{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":350,"targetDuration":352,"studyType":66,"phases":4,"briefSummary":353,"conditions":354,"keywords":357,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":117},"100625448","comparison-of-non-invasive-mean-arterial-blood-pressure-measurements-at-the-arm-and-ankle-during-elective-cesarean-delivery-100625448","NCT07422766","Comparison of Non-Invasive Mean Arterial Blood Pressure Measurements at the Arm and Ankle During Elective Cesarean Delivery.","Observational Study Comparing Non-Invasive Mean Arterial Blood Pressure Measurements at the Arm and Ankle During Elective Cesarean Delivery to Facilitate Skin-to-Skin Contact.","Inclusion Criteria:\n\n* Women scheduled for elective cesarean under neuraxial anesthesia at CHU Sainte-Justine.\n* American Society of Anesthesiologists Physical Status I-III\n* Singleton pregnancy\n* Gestation ≥ 35 weeks\n* BMI \\\u003C 40\n* Able to consent in French or English\n\nExclusion Criteria:\n\n* Cesarean planned under general anesthesia.\n* Multiple pregnancy\n* Prematurity \\\u003C 35 weeks gestation\n* Major fetal anomalies\n* Morbid obesity (BMI ≥ 40)\n* Active labor\n* Emergency cesarean\n* Prisoners\n* Peripheral vascular disease requiring medication or treatment\n* Hypertensive diseases requiring medication\n* Inability to place blood pressure cuff on ankle (amputation, dysmorphism, etc.)\n* Complications requiring significant hemodynamic support (transfusions, inotropes, multiple vasopressors, etc.",{"count":351,"type":22},110,"1 Day","This observational study aims to compare mean arterial pressure measurements obtained using an ankle blood pressure cuff with those obtained using a standard upper-arm cuff in pregnant individuals undergoing elective cesarean delivery under spinal anesthesia. The primary objective is to determine the level of agreement between the two measurement sites.The main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\nDemonstrate that the mean arterial pressure is similar between arm and ankle with the blood pressure cuff\n\nEvery participant will be their own control. (Measurements will be taken at both sites on every participant)",[244,28,355,356],"Blood Pressure Measurement in Pregnancy","Skin to Skin Contact",[358,359,360,181,361],"blood pressure","Mean arterial pressure","pregnancy","skin to skin","2026-03-23",{"date":364,"type":48},"2026-03-27",{"date":366,"type":48},"2026-02-26",{"date":368,"type":22},"2026-12",{"name":370,"class":84},"St. Justine's Hospital",{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":378,"enrollmentInfo":379,"targetDuration":4,"studyType":23,"phases":381,"briefSummary":382,"conditions":383,"keywords":384,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":117},"100547823","post-operative-cesarean-section-cosmesis-100547823","NCT06412978","Post-Operative Cesarean Section Cosmesis","Post-Operative Cosmesis and Skin Closure Methods After Cesarean Section","Inclusion Criteria:\n\n* Age 18-44\n* Any race\n* Any parity\n* Scheduled cesarean section\n* Neuraxial analgesia\n\nExclusion Criteria:\n\n* Non-English Speaking\n* Incarcerated\n* Maternal Connective Tissue Disorder\n* Systemic maternal steroid use\n* Three prior cesarean deliveries\n* Body Mass Index (BMI) \\>40","44 Years",{"count":380,"type":22},52,[96],"Given the high numbers of cesarean deliveries being performed today, there has been interest in optimizing surgical techniques. Several recent reviews have summarized the evidence for various steps of cesarean delivery, but surprisingly in many cases there is little scientific evidence on which to base the choice of surgical technique.",[28],[385,386,387],"cosmetic improvement","surgical correction","Cosmesis","2026-03-13",{"date":390,"type":48},"2026-03-16",{"date":392,"type":48},"2024-09-05",{"date":394,"type":22},"2026-10",{"name":396,"class":84},"Wake Forest University Health Sciences",{"id":398,"slug":399,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":404,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":407,"briefSummary":408,"conditions":409,"keywords":413,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":423,"locationsCount":117},"100587189","phase-4-comfort-trial-complex-obstetric-management-with-focused-regional-transversus-abdominis-plane-block-100587189","NCT06925152","COMFORT Trial: Complex Obstetric Management With Focused Regional Transversus Abdominis Plane Block","COMFORT","Inclusion criteria:\n\nPatient has a history of a least one of the following:\n\n* Prior exploratory laparotomy\n* History of non-obstetric open intra-abdominal surgery\n* History of three or more prior cesarean deliveries\n* History of intra-abdominal or pelvic adhesive disease\n* History of abdominoplasty\n* History of abdominal re-exploration surgery\n\nExclusion Criteria:\n\n* Received general anesthesia\n* History of less than 3 cesarean deliveries if do not meet other inclusion criteria\n* History of chronic opioid use\n* History of substance abuse (i.e. alcohol, methamphetamine\u002Famphetamine, abuse of prescription opioid medication, or heroin use)\n* History of chronic kidney disease\n* Allergies to bupivacaine or oral analgesics\n* Patient preference\n* Cesarean hysterectomy\n* Administration of ≥4mg morphine to epidural\n* Loss to follow-up","50 Years",{"count":406,"type":22},120,[172],"To assess the effect of intraoperative transversus abdominis plane (TAP) blocks on the amount of opioid pain medications expressed as morphine milliequivalents (MME) used postoperatively in patients who have undergone cesarean delivery (CD) in the setting of complex obstetric surgery (COS).",[410,411,28,412],"Complex Obstetric Surgery","Perioperative Pain Management","Postoperative Pain Control",[414,415,329,416],"Complex obstetric surgery","Perioperative pain management","postoperative pain control","2026-03-08",{"date":419,"type":48},"2026-03-11",{"date":421,"type":48},"2025-07-15",{"date":193,"type":22},{"name":424,"class":84},"University of Tennessee",{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":63,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":434,"briefSummary":435,"conditions":436,"keywords":437,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":117},"100622990","prophylactic-tranexamic-acid-in-low-risk-repeat-cesarean-delivery-a-randomized-controlled-trial-100622990","NCT07390799","Prophylactic Tranexamic Acid in Low-Risk Repeat Cesarean Delivery: A Randomized Controlled Trial","Effect of Prophylactic Tranexamic Acid Administered After Fetal Delivery on Perioperative Blood Loss and Neonatal Outcomes in Low-Risk Repeat Cesarean Delivery: A Randomized Controlled Trial","Inclusion Criteria:\n\nWomen aged 18 to 45 years Singleton pregnancy Gestational age ≥37+0 weeks Scheduled second or third cesarean delivery Classified as low risk for postpartum hemorrhage Ability to provide written informed consent Planned cesarean delivery under regional or general anesthesia\n\nExclusion Criteria:\n\nPrimary cesarean delivery More than three previous cesarean deliveries Placenta previa, placenta accreta spectrum, or suspected abnormal placentation Multiple pregnancy Known coagulation disorders or use of anticoagulant therapy History of thromboembolic disease Severe anemia (hemoglobin \\\u003C10 g\u002FdL) Hypertensive disorders of pregnancy (including preeclampsia or eclampsia) Intrauterine fetal demise Emergency cesarean delivery Known hypersensitivity to tranexamic acid",{"count":433,"type":22},204,[96],"Postpartum hemorrhage remains a leading cause of maternal morbidity following cesarean delivery. Tranexamic acid (TXA) has been shown to reduce blood loss when used for the treatment of postpartum hemorrhage; however, its routine prophylactic use during cesarean delivery, particularly in low-risk women, remains controversial. Large randomized trials have demonstrated limited benefit on major maternal outcomes, and data regarding clinically meaningful blood loss reduction and neonatal safety are still inconclusive.\n\nThis randomized controlled trial aims to evaluate the effect of prophylactic tranexamic acid administered after fetal delivery on perioperative blood loss in women undergoing low-risk repeat cesarean delivery. Secondary objectives include the assessment of neonatal outcomes to further evaluate the safety of routine TXA administration in this population.\n\nThe results of this study are expected to provide evidence to inform clinical decision-making regarding the routine use of tranexamic acid in low-risk repeat cesarean deliveries, balancing potential maternal benefits against neonatal safety considerations.",[28],[33,438,439],"Repeat Cesarean Section","Perioperative Blood Loss","2026-01-29",{"date":442,"type":48},"2026-02-05",{"date":444,"type":22},"2026-02-01",{"date":446,"type":22},"2026-09-30",{"name":448,"class":84},"Ege University",{"id":450,"slug":451,"hasResults":11,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":11,"sex":17,"minAge":456,"maxAge":457,"enrollmentInfo":458,"targetDuration":4,"studyType":23,"phases":459,"briefSummary":460,"conditions":461,"keywords":462,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":117},"100617730","phase-4-hemodynamics-during-cesarean-delivery-under-spinal-anesthesia-with-norepinephrine-versus-ephedrine-100617730","NCT07322419","Hemodynamics During Cesarean Delivery Under Spinal Anesthesia With Norepinephrine Versus Ephedrine","Echocardiographic Evaluation of Cardiac Output During Cesarean Delivery Under Spinal Anesthesia Using Norepinephrine Versus Ephedrine: A Randomized Controlled Trial","Inclusion Criteria:\n\n* American Society of Anesthesiologists physical status II.\n* Singleton, full term pregnancy.\n* Scheduled cesarean delivery under spinal anesthesia.\n\nExclusion Criteria:\n\n* Height \\\u003C150 or \\>180 cm.\n* Weight \\\u003C60 or \\>110 kg.\n* Body mass index (BMI) \\\u003C18.5 or ≥35 kg\u002Fm².\n* Women presenting in labor.\n* Any contraindication to spinal anesthesia: increased intracranial pressure, coagulopathy, or local skin infection.\n* Chronic or pregnancy-induced hypertension.\n* Baseline systolic blood pressure \\>140 mm Hg.\n* Hemoglobin \\\u003C10 g\u002Fdl.\n* Diabetes mellitus, cardiovascular, cerebrovascular, or renal disease.\n* Polyhydramnios or known significant fetal abnormalities.\n* Current administration of vasoactive drugs such as: beta blockers, salbutamol, or thyroxin.","19 Years","40 Years",{"count":65,"type":22},[172],"Echocardiography will be used to measure cardiac output and calculate other important hemodynamic variables in healthy patients with full-term singleton pregnancy during cesarean delivery under conventional spinal anesthesia using 2 different vasopressor drugs: norepinephrine in 1 group versus ephedrine in another group.",[28,176],[212,211,463,464],"Echocardiography","Hemodynamics","2026-01-12",{"date":467,"type":48},"2026-01-14",{"date":469,"type":48},"2026-01-01",{"date":471,"type":22},"2026-12-31",{"name":473,"class":84},"Mansoura University",{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":17,"minAge":482,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":23,"phases":485,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":117},"100600834","phase-4-post-cesarean-analgesia-comparing-effectiveness-of-staggered-v-simultaneous-therapies-100600834","NCT07102641","Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies","PACESS: Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies","PACESS","Inclusion Criteria:\n\n* \\>\u002F= 34 weeks gestation\n* Singleton pregnancy\n* Delivery via cesarean section under regional anesthesia\n\nExclusion Criteria:\n\n* Contraindication to acetaminophen or NSAIDs\n* Current or history of opioid use or misuse\n* Intrauterine fetal demise\n* Major congenital anomaly\n* Conversion to general anesthesia intra-op or planned general anesthesia\n* Mid-line vertical skin incision\n* Receipt of intraoperative local analgesia such as Transversus Abdominis Plan (TAP) block or wound infiltration","16 Years",{"count":484,"type":22},825,[172],"Cesarean delivery is a commonly performed surgical procedure associated with worse postpartum pain when compared to vaginal birth. Uncontrolled postpartum pain is associated with increased neonatal and maternal risks. Multimodal non-opioid pain medications, including acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) are the preferred first-line therapies. There is no standard practice, however, on best dosing schedules (ie staggered or different time v. simultaneous or same time). This protocol describes a randomized clinical trial aimed to determine whether staggered dosing of acetaminophen and NSAIDs in superior to simultaneous dosing in controlling post-cesarean pain.",[28,488,489,490,491,492],"Postpartum Comfort","Postpartum Pain","Post-operative Pain","NSAIDs","Acetaminophen (D000082)","2025-09-02",{"date":495,"type":48},"2025-09-03",{"date":497,"type":48},"2025-08-26",{"date":499,"type":22},"2027-12",{"name":501,"class":84},"Thomas Jefferson University",{"id":503,"slug":504,"hasResults":11,"nctId":505,"briefTitle":506,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":23,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":4},"100600231","phase-4-comparison-of-intrathecal-bupivacaine-with-and-without-morphine-for-post-operative-analgesia-in-parturients-undergoing-elective-cesarean-section-a-randomized-controlled-trial-100600231","NCT07094802","Comparison of Intrathecal Bupivacaine With and Without Morphine for Post-operative Analgesia in Parturients Undergoing Elective Cesarean Section: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Parturients undergoing elective caesarean section under Spinal anesthesia\n* ASA PS II, III\n* \\> 18 years\n\nExclusion Criteria:\n\n* Refusal to Participate\n* Contraindications to spinal anaesthesia and adjuvants INR ≥ 1.5 Plateletes \\\u003C 1,00,000\u002Fcumm Severe aortic stenosis, and\u002For severe mitral stenosis Infection at lumbar puncture site Known allergy to local anesthetics and opioids\n* Communication barrier\n* Height \\\u003C150 cm",{"count":509,"type":22},92,[172],"The goal of this clinical trial is to compare intrathecal bupivacaine with or without morphine for postoperative analgesia in patients undergoing elective cesarean section. The main questions it aims to answer are:\n\nIs intrathecal bupivacaine with morphine superior to intrathecal bupivacaine alone for postoperative analgesia for parturients undergoing cesarean section? What is the duration of analgesia in the two groups? Researchers will compare drug intrathecal bupivacaine with morphine to a iintrathecal bupivacaine alone to see if intrathecal morphine has benefits for psotoperative analgesia .\n\nParticipants will:\n\nGet intrathecal bupivacaine with Morphine or intrathecal bupivacaine alone during spinal anesthesia for cesarean section.\n\nThey will be followed up for NRS pain scores and side effects for 24 hours. Time to need of first rescue analgesic will be noted",[513,28,514],"Postoperative Pain","Analgesia, Obstetrical","2025-07-23",{"date":158,"type":48},{"date":518,"type":22},"2025-10-15",{"date":520,"type":22},"2026-08-15",{"name":522,"class":84},"Tribhuvan University Teaching Hospital, Institute Of Medicine.",{"id":524,"slug":525,"hasResults":11,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":545},"100587395","frequency-of-occurrence-and-risk-factors-of-postoperative-nausea-and-vomiting-during-elective-c-section-under-spinal-anesthesia-with-preventive-medication-100587395","NCT06927830","Frequency of Occurrence and Risk Factors of Postoperative Nausea and Vomiting During Elective C-section Under Spinal Anesthesia With Preventive Medication","Incidence and Risk Factors of Postoperative Nausea and Vomiting (PONV) During Elective C-Section Under Spinal Anesthesia With Multimodal Antiemetic Prophylaxis","Inclusion Criteria:\n\nAny patient requiring elective caesarean section under spinal anesthesia, at a gestational age \\>37 weeks of amenorrhea in the context of a single-fetal pregnancy.\n\nExclusion Criteria:\n\nFailure to understand the French language; Contraindication to locoregional anesthesia; Nausea and\u002For vomiting in the 24 hours preceding the procedure; Type 1 or type 2 insulin-requiring non-gestational diabetes; Allergy or contraindication to one of the products used in the usual management protocol; Severe preeclampsia; Height \\\u003C150 cm",{"count":531,"type":22},400,"The aim of this study is to learn about the incidence and risk factors of nausea and vomiting during planned caesarean section under spinal anesthesia.\n\nThe main question it aims to answer is : What are the incidence and risks factors of postoperative nausea and vomiting (NV) during planned caesarean section under spinal anesthesia with administration of intrathecal morphine and multimodal antiemetic prophylaxis ?\n\nPatients who will be managed according to the standard protocol in use in the department will have to answer specific questions about NV in the post-interventional recovery room and on 2 further visits in the first 24 hours post-caesarean section.",[534,28,70,535],"Nausea and Vomiting, Postoperative","Antiemetic Therapy","2025-04-14",{"date":538,"type":48},"2025-04-15",{"date":540,"type":48},"2025-03-19",{"date":542,"type":22},"2026-04",{"name":544,"class":84},"University of Liege",2,{"id":547,"slug":548,"hasResults":11,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":552,"eligibilityCriteria":553,"healthyVolunteers":16,"sex":17,"minAge":456,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":556,"conditions":557,"keywords":559,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":117},"100583862","duration-of-urinary-catheterization-following-cesarean-deliveries-under-neuraxial-anesthesia-100583862","NCT06881849","Duration of Urinary Catheterization Following Cesarean Deliveries Under Neuraxial Anesthesia","Duration of Urinary Catheterization Following Cesarean Deliveries Under Neuraxial Anesthesia: A Prospective Cohort Study","DUCC","Inclusion Criteria:\n\n* Patients ≥19 years of age.\n* Undergoing cesarean delivery (elective or emergent) at BC Women's Hospital.\n* Neuraxial anesthesia as their primary mode of anesthesia (spinal, epidural, combined spinal-epidural, dural-puncture epidural).\n* In-patient status at 24 (+\u002F- 8) hours.\n* Self-reported proficiency in speaking and reading English.\n\nExclusion Criteria:\n\n* Refusal to participate.\n* Inability to provide informed consent.\n* Other surgery (i.e. cervical cerclage) or delivery modes (i.e. operative vaginal delivery).\n* De novo general anesthetic, or patients who had a conversion from neuraxial to a general anesthetic.\n* Communication from patient's nurse indicating that it is not appropriate to approach due to distressing birth experience and\u002For outcome.",{"count":555,"type":22},300,"In cesarean deliveries, urinary catheters are often used to help empty the bladder while patients have limited mobility. These catheters typically stay in during early recovery because certain pain medications can make it hard for patients to urinate. Recently, the Society of Obstetric Anesthesia and Perinatology (SOAP) recommended removing catheters within 6-12 hours after delivery to aid recovery. However, at BC Women's Hospital, a review found that catheters stayed in for an average of 19 to 19.4 hours, even when patients were mobile.\n\nLeaving catheters in too long can increase the risk of urinary tract infections (UTIs), pain, and urination issues, which can delay recovery and extend hospital stays. An internal review showed that factors like patient anxiety may affect when catheters are removed. Postpartum anxiety affects around 9.9% to 20.7% of new mothers in the first year and is an important factor in recovery after a cesarean delivery.\n\nThe main goal of this study is to look at how long urinary catheters stay in patients who had a cesarean delivery under spinal or epidural anesthesia, and what the score is from a questionnaire used to measure anxiety called the State Trait Anxiety Inventory (STAI-S), to see if there is a link between them.",[28,558],"Urinary Catheterization",[560,329,561,562,563],"patient recovery","urinary catheterization","foley catheter","patient anxiety","2025-03-11",{"date":566,"type":48},"2025-03-18",{"date":568,"type":22},"2025-04-25",{"date":570,"type":22},"2025-12-01",{"name":572,"class":84},"University of British Columbia",{"id":574,"slug":575,"hasResults":11,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":579,"eligibilityCriteria":580,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":23,"phases":583,"briefSummary":584,"conditions":585,"keywords":586,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":594,"leadSponsor":595,"locationsCount":4},"100568657","the-effectiveness-of-a-care-bundle-to-prevent-postpartum-hemorrhage-after-cesarean-delivery-100568657","NCT06684080","The Effectiveness of a Care Bundle to Prevent Postpartum Hemorrhage After Cesarean Delivery","A Cluster Randomized Trial on the Effectiveness of a Care Bundle to Prevent Postpartum Hemorrhage After Cesarean Delivery (Re-Team)","RE-TEAM","Inclusion Criteria:\n\n* Hospital level\n\n  1. Public hospitals\n  2. There are more than 100 cesarean deliveries per year\n* Patient level\n\n  1. Cesarean delivery\n  2. Sign informed consent\n\nExclusion Criteria:\n\n* Hospital level\n\n  1\\. Data verification information cannot be provided\n* Pregnant woman level 1. No blood routine results within 2 weeks before surgery",{"count":582,"type":22},52000,[96],"Delays in the detection or inconsistent use of effective interventions of postpartum hemorrhage can result in complications or death. We designed a cluster-randomized trial to assess a multi-component strategy for the detection and treatment of postpartum hemorrhage after cesarean delivery.",[28],[38,329,587,588,589],"Randomized trial","Detection","treatment","2024-12-31",{"date":592,"type":48},"2025-01-01",{"date":592,"type":22},{"date":160,"type":22},{"name":596,"class":84},"Dunjin Chen"]